Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Teams Up with US Academia to Develop Novel TB Drugs
April 17, 2018
- Taisho Files Taurine for Recurrence Prevention of Stroke-Like Episodes in MELAS in Japan
April 17, 2018
- Tecentriq to Provide New Option for NSCLC: Oncologists
April 16, 2018
- Asian Regenerative Medicine Associations Held 1st Symposium on Regulatory Harmonization in Tokyo
April 16, 2018
- Takeda CEO Eager to Lure More Partners to Shonan iPark, Says Diversity Is Source of Creativity
April 16, 2018
- Shonan Health Innovation Park Marks Grand Opening: Takeda
April 16, 2018
- Oncodesign Partners with Erytech to Support Preclinical Development of Anticancer Drugs
April 16, 2018
- Mylan Gets EU Rights for Fujifilm Kyowa Kirin Biologics’ Humira Biosimilar
April 12, 2018
- Chugai Drops Patent Suit over Nippon Kayaku’s Herceptin Biosimilar
April 12, 2018
- Japan Ethical Drug Sales Total 9.9 Trillion Yen in FY2017: Encise Snapshot
April 11, 2018
- Mitsubishi Tanabe’s ALS Drug Filing Accepted for Review in Canada
April 11, 2018
- Takeda Carve-Out Venture Boots Up with 250 Million Yen Seed Round
April 11, 2018
- Hisamitsu’s Japan Ethical Drug Sales Down 3.1% in FY2017
April 11, 2018
- Mitsubishi Tanabe Files with International Court for Upfront Payment Return from S. Korean Firm
April 11, 2018
- Osaka Univ. Spinout, Sumitomo Dainippon Strike Option Deal on Antibody-Inducing Peptides
April 10, 2018
- Otsuka Partners with Takara Bio to Codevelop Gene Therapy Products with Exclusive Sales Rights in Japan
April 10, 2018
- Ethical Drug Sales Up 1.0% in February: Crecon Report
April 9, 2018
- Kowa Gets High Court Backing in Livalo Patent Suit
April 9, 2018
- Alfresa to Fully Introduce Distribution Cost Analysis System; Will “Raise Reps’ Awareness of Importance of Price Negotiations”: Pres.
April 9, 2018
- Japan Generic Market Projected at 1.2 Trillion Yen in 2021: Fuji Keizai
April 6, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…